The estimated Net Worth of Robert Dee Etherington is at least $912 Thousand dollars as of 29 July 2024. Mr Etherington owns over 27,320 units of Clene Nanomedicine stock worth over $183,607 and over the last 4 years he sold CLNN stock worth over $110,840. In addition, he makes $617,508 as CEO and Pres & Director at Clene Nanomedicine.
Mr has made over 3 trades of the Clene Nanomedicine stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 27,320 units of CLNN stock worth $81,960 on 29 July 2024.
The largest trade he's ever made was exercising 27,320 units of Clene Nanomedicine stock on 29 July 2024 worth over $81,960. On average, Mr trades about 6,891 units every 67 days since 2021. As of 29 July 2024 he still owns at least 30,149 units of Clene Nanomedicine stock.
You can see the complete history of Mr Etherington stock trades at the bottom of the page.
Robert Etherington is the CEO, Pres & Director at Clene Nanomedicine.
As the CEO and Pres & Director of Clene Nanomedicine, the total compensation of Mr Etherington at Clene Nanomedicine is $617,508. There are no executives at Clene Nanomedicine getting paid more.
Mr Etherington is 53, he's been the CEO and Pres & Director of Clene Nanomedicine since . There are 3 older and 2 younger executives at Clene Nanomedicine. The oldest executive at Clene Nanomedicine Inc. is Dr. Robert Glanzman M.D., 64, who is the Chief Medical Officer.
Robert's mailing address filed with the SEC is 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121.
Over the last 4 years, insiders at Clene Nanomedicine have traded over $1,293,164 worth of Clene Nanomedicine stock and bought 19,236,803 units worth $21,152,263 . The most active insiders traders include David J Matlin, Chidozie Ugwumba, and Alison Mosca. On average, Clene Nanomedicine executives and independent directors trade stock every 26 days with the average trade being worth of $2,786,272. The most recent stock trade was executed by Robert Dee Etherington on 29 July 2024, trading 27,320 units of CLNN stock currently worth $81,960.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.
Clene Nanomedicine executives and other stock owners filed with the SEC include: